Literature DB >> 26069378

Dofetilide induced trigeminal neuralgia.

Hayan Al Maluli1.   

Abstract

Anti-arrhythmic medications are uncommonly used due to their pro-arrhythmic effect. However, just like any other class of medication, they can cause idiosyncratic reactions that may or may not be related to their mechanism of action. Those reactions can be severe enough to warrant discontinuation of a successful therapeutic intervention. In this case, we present a case of trigeminal neuralgia caused by dofetilide.

Entities:  

Keywords:  Adverse effects; dofetilide; trigeminal neuralgia

Mesh：

Substances：

Year:  2015        PMID： 26069378      PMCID： PMC4450566          DOI： 10.4103/0253-7613.157138

Source DB:  PubMed          Journal:  Indian J Pharmacol        ISSN： 0253-7613            Impact factor:   1.200


  4 in total

1.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  L Samuel Wann; Anne B Curtis; Craig T January; Kenneth A Ellenbogen; James E Lowe; N A Mark Estes; Richard L Page; Michael D Ezekowitz; David J Slotwiner; Warren M Jackman; William G Stevenson; Cynthia M Tracy; Valentin Fuster; Lars E Rydén; David S Cannom; Jean-Yves Le Heuzey; Harry J Crijns; James E Lowe; Anne B Curtis; S Bertil Olsson; Kenneth A Ellenbogen; Eric N Prystowsky; Jonathan L Halperin; Juan Luis Tamargo; G Neal Kay; L Samuel Wann; Alice K Jacobs; Jeffrey L Anderson; Nancy Albert; Judith S Hochman; Christopher E Buller; Frederick G Kushner; Mark A Creager; Erik Magnus Ohman; Steven M Ettinger; William G Stevenson; Robert A Guyton; Lynn G Tarkington; Jonathan L Halperin; Clyde W Yancy
Journal:  Circulation       Date:  2010-12-20       Impact factor: 29.690

2.  Guidelines for submitting adverse event reports for publication.

Authors:  William N Kelly; Felix M Arellano; Joanne Barnes; Ulf Bergman; I Ralph Edwards; Alina M Fernandez; Stephen B Freedman; David I Goldsmith; Kui Huang; Judith K Jones; Rachel McLeay; Nicholas Moore; Rosie H Stather; Thierry Trenque; William G Troutman; Eugene van Puijenbroek; Frank Williams; Robert P Wise
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-05       Impact factor: 2.890

3.  Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study.

Authors:  S Singh; R G Zoble; L Yellen; M A Brodsky; G K Feld; M Berk; C B Billing
Journal:  Circulation       Date:  2000-11-07       Impact factor: 29.690

4.  Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectoris.

Authors:  M L Sedgwick; H S Rasmussen; S M Cobbe
Journal:  Am J Cardiol       Date:  1992-02-15       Impact factor: 2.778
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.